Parkinson's disease

Psychiatric Clinics of North America

Volumn 20, Issue 4, 1997, Pages 769-790

  Barbosa, E R ^a   Limongi, J C P ^a   Cummings, J L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; TOXIN;

AGING; AKINESIA; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; MUSCLE RIGIDITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREMOR;

EID: 0031459717     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(05)70344-0     Document Type: Article

References (76)

1. R.D. Adams L. van Bogaert H. van der Eecken Striato-nigral degeneration J Neuropathol Exp Neurol 23 1964 584
2. B.J. Beck Neuropsychiatric manifestations of Lewy body disease J Geriatr Psychiatry Neurol 8 1995 189
3. J. Berciano Olivopontocerebellar atrophy J. Jankovic E. Tolosa Parkinson's Disease and Movement Disorders 1993 Williams & Wilkins Baltimore 163
4. T. Brannan M. Yahr Comparative study of selegiline plus l -dopa-carbidopa versus l -dopa-carbidopa alone in the treatment of Parkinson's disease Ann Neurol 37 1995 95
5. A. Brusa P.F. Peloso An Introduction to Progressive Supranuclear Palsy, Steele-Richardson-Olszelwski Syndrome 1993 John Libbey Roma 3
6. 18F-DOPA and positron emission tomography Neurology 42 1992 1894 1900
7. W. Byrkmayer J. Knoll P. Riederer Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study J Neural Transm 64 1985 113
8. D.B. Calne Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44 1994 5 10
9. R. Cantello M. Aguggia M. Gilli Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the “hedonic” dopamine synapse J Neurol Neurosurg Psychiatry 52 1989 724 731
10. T.N. Chase M. Mouradian T.M. Engber Motor response complications and the function of striatal efferent systems Neurology 43 supp 6 1993 523
11. G.G. Celesia A.N. Barr Psychosis and other psychiatric manifestations of levodopa therapy Arch Neurol 23 1970 193
12. S.J. Collins J.E. Ahlskog J.E. Parisi Progressive supranuclear palsy neuropathologically based diagnostic criteria J Neurol Neurosurg Psychiatry 58 1995 167
13. C.G. Cotzias M.H. van Woert L.M. Schiffer Aromatic aminoacids and modification of parkinsonism N Engl J Med 276 1967 374
14. J.L. Cummings Behavioral complications of drug treatment of Parkinson's disease J Am Geriatr Soc 39 1991 708
15. J.L. Cummings Depression and Parkinson's disease: A review Am J Psychiatry 149 1992 443 454
16. J.L. Cummings Intellectual impairment in Parkinson's disease: Clinical, pathological and biochemical correlates J Geriatr Psychiatr Neurol 1 1988 24 36
17. J.L. Cummings Subcortical dementia: Neuropsychology, neuropsychiatry and pathology Br J Psychiatry 149 1986 682 697
18. D.A. Drachman Ophthalmoplegia plus: The neurodegenerative disorders associated with progressive external ophthalmoplegia Arch Neurol 18 1968 654
19. E. Dupont A. Andersen J. Boas Sustained-release Madopar HBS compared with standard Madopar in the long-term of “de novo” parkinsonian patients Acta Neurol Scand 93 1996 14
20. R.C. Duvoisin Genetics of Parkinson's disease Adv Neurol 45 1987 307 312
21. H. Ehringer O. Hornykiewicz Verteilung von Noradrenalin und Dopamin (3-Hydroxy-tyramin) im Gehrin des Menschen und ihr bei Erkrankungen des extrapyramidalen Systems Klin Wschr 38 1960 1236
22. R. Faber M.R. Trimble Electroconvulsive therapy in Parkinson's disease and other movement disorders Mov Disord 6 1991 293
23. S.A. Factor E.S. Molho G.D. Podskalny Parkinson's disease: Drug-induced psychiatric states W.J. Weiner A.E. Lang Behavioral Neurology of Movement Disorders 1995 Raven New York 115
24. S. Fahn Secondary Parkinsonism E.S. Goldensohn S.H. Appel Scientific Approaches to Clinical Neurology 1977 Lea & Febiger Philadelphia 1159
25. S. Fahn G. Cohen The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it Ann Neurol 32 1992 804 812
26. J.M. Fearnley A.J. Lees Aging and Parkinson's disease: Substantia nigra regional selectivity Brain 114 1991 2283 2301
27. L. Forno Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 1996 259
28. L.S. Forno J.W. Langston L.E. Delaney An electron microscopic study of MPTP-induced inclusion bodies in an old monkey Brain Res 448 1988 150 157
29. C.G. Goetz C.M. Tanner R.H. Glantz Chronic agonist therapy for Parkinson's disease: A 5-year study of bromocriptine and pergolide Neurology 35 1985 749 751
30. C.G. Goetz C.M. Tanner H.L. Klawans Pharmacology of hallucinations induced by long-term drug therapy Am J Psychiatry 139 1982 494
31. L. Golbe P.H. Davies Progressive supranuclear palsy E. Tolosa J. Jankovic Parkinson's Disease and Movement Disorders 1993 Williams & Wilkins Baltimore 45
32. F.K. Goodwin Psychiatric side effects of levodopa in man JAMA 218 1971 1915
33. I.G. Graham D.R. Oppenheimer Orthostatic hypotension and nicotinic sensitivity in a case of multiple system atrophy J Neurol Neurosurg Psychiatry 2 1969 28
34. A. Hirano L.T. Kurland R.S. Krooth Parkinsonism-dementia complex, an endemic disease on the island of Guam: Clinical features: II. Pathologic features Brain 84 1961 642
35. Hughes A.J. Daniel S.E. Kilford L. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181
36. J. Jankovic Pergolide: Clinical experience Y. Agyd Current Trends in the Treatment of Parkinson's Disease 1992 John Libbey London 93
37. E.N.H. Jansen Steur Increase of Parkinson disability after fluoxetine medication Neurology 13 1993 211
38. P. Jenner A.H.V. Schapira C.D. Marsden New insights into the cause of Parkinson's disease Neurology 42 1992 2241 2250
39. W.G. Johnson S.E. Hodge R.C. Duvoisan Twin studies and the genetics of Parkinson's disease—a reappraisal Mov Disord 5 1990 187 194
40. J.W. Langston L.S. Forno C.S. Robert I. Irwin MPTP causes selective damage to the zona compacta of the substantia nigra to the squirrel monkey Brain Res 292 1984 390 394
41. H.D. Langstry S.P. Clissold Pergolide: A review of its pharmacological properties an therapeutic potential in Parkinson's disease Drugs 39 1990 491
42. A.J. Lees Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease BMJ 311 1995 1602
43. P.A. Lewitt C.D. Ward T.A. Larsen Comparison of pergolide and bromocriptine therapy in Parkinsonism Neurology 33 1983 1009
44. A.N. Lieberman G. Goppinathan A. Neophytides Management of levodopa failures: The use of dopamine agonists Clin Neuropharmacol 9 1986 59
45. R.J. Martilla U.K. Rinne Dementia in Parkinson's disease Acta Neurol Scand 54 1976 431 441
46. R. Mayeux Y. Stern L. Cote J.B.W. Williams Altered serotonin metabolism in depressed patients with Parkinson's disease Neurology 34 1984 642 646
47. R. Mayeux Y. Stern J.B.W. Williams Clinical and biochemical features of depression in Parkinson's disease Am J Psychiatry 143 1986 756 759
48. J.L. Montastruc J.M. Senard P. Verwaerde Fluoxetine in orthostatic hypotension of Parkinson's disease: A clinical and experimental study Mov Disord 11 supp 1 1996 116
49. P. Nausieda W. Weiner L. Kaplan Sleep disruption in the course of chronic levodopa therapy: An early feature of the levodopa psychosis Clin Neuropharmacol 5 1982 183
50. P.A. Nausieda C.M. Tanner H.L. Klawans Serotonergically active agents in levodopa-induced psychiatric toxicity reactions Adv Neurol 37 1983 23
51. H. Ozaki L.E. Lipkin S.M. Aronson Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadroparesis in flexion J Neuropathol Exp Neurol 20 1961 237
52. W.D. Parker S.J. Boyson J.K. Parks Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann Neurol 26 1989 719 723
53. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa Ann Neurol 39 1996 29
54. G. Pezzoli E. Martignoni C. Pacchetti Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study Mov Disord 9 1994 431
55. N.P. Quinn Multiple system atrophy C.D. Marsden S. Fahn Movement Disorders ed 3 1994 Butterworth-Heineman Oxford 262
56. A.H. Rajput B. Rozdilsky A. Rajput Accuracy of clinical diagnosis of parkinsonism: A prospective study Can J Neurol Sci 18 1991 275
57. A.H. Rajput A.P. Offord C.M. Bear Epidemiology of Parkinson's disease: Incidence, classification and mortality Ann Neurol 16 1984 78 132
58. J.J. Rebeiz E.H. Kolodny E.P. Richardson Corticodentatonigral degeneration with neuronal achromasia Arch Neurol 18 1968 20
59. J.O. Rinne M.S. Lee P.D. Thompson Corticobasal degeneration: A clinical study of 36 cases Brain 117 1994 1183
60. U.K. Rinne Early dopamine agonist treatment in Parkinson's disease Adv Neurol 53 1990 417
61. G.S. Robertson H.A. Robertson Synergistic effects of D1 and D2 dopamine agonists on turning behavior in rats Brain Res 384 1986 387
62. Rybicki B.A. Johnson C.C. Uman J. Parkinson's disease mortality and the industrial use of heavy metals in Michigan Mov Disord 8 1993 87 92
63. A.H.V. Schapira Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal Mov Disord 9 1994 25 38
64. R.S. Schwab A.C. England D.E. Poskanzer Amantadine in the treatment of Parkinson's disease JAMA 208 1969 1168
65. G.M. Shy G.A. Drager A neurological syndrome associated with orthostatic hypotension: A clinical pathological study Arch Neurol 2 1960 511
66. J. Sian D.T. Dexter A.J. Lees Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 1994 348 355
67. P.S. Spencer P.B. Nunn J.S. Hugon Guam amyotrophic lateral sclerosis-parkinsonism and dementia linked to a plant excitant neurotoxin Science 237 1987 517
68. M. Stacy J. Jankovic Differencial diagnosis of Parkinson's disease and the parkinsonism-plus syndromes Neurol Clin 10 1992 341
69. S.E. Starkstein T.J. Preziosi P.L. Bolduc Depression in Parkinson's disease J Nerv Ment Dis 178 1990 27 31
70. J.C. Steele J.C. Richardson J. Olszewski Progressive supranuclear palsy: A heterogeneous degeneration involving brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia Arch Neurol 10 1964 333
71. E. Tandberg J.P. Larsen D. Aarsland The occurrence of depression in Parkinson's disease Arch Neurol 53 1996 175 179
72. J.W. Tetrud J.W. Langston P.L. Garbe A.J. Ruttenber Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1-2-3-6-tetrahydropyridine (MPTP) Neurology 39 1989 1483 1487
73. R.J. Uitti C.M. Tanner A.H. Pajput Hypersexuality with antiparkinsonian therapy Clin Neuropharmacol 12 1989 375
74. F. Valdeoriolla E. Tolosa J. Valls-Solé Differential diagnosis and clinical diagnostic criteria of progressive supranuclear palsy L. Battistin G. Scarlato T. Caraceni Parkinson's Disease: Advances in Neurology 69 1996 Lippincott-Raven Philadelphia 405
75. J.L. Vitek Stereotaxic surgery and deep brain stimulation for Parkinson's disease and movement disorders R.L. Watts W.C. Koller Movement Disorders: Neurologic Principles and Practice 1997 McGraw-Hill New York 237
76. J. Zoldan G. Friedberg M. Livneh Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist Neurology 45 1995 1305